Physician profile
Harold Steven Silver
NPI 1861461899
$9,107.01
in general payments reported to CMS, 2019-2025
31 companies · $802 in 2025
The $802 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $916 · 2020: $663 · 2021: $1,785 · 2022: $1,607 · 2023: $1,714 · 2024: $1,622 · 2025: $802.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,103 · Education: $34.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,103.05 |
| Education | $34.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,286.79 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $1,272.12 | 2019-2025 | Entyvio, Eohilia |
| Pfizer INC. | $873.02 | 2019-2025 | |
| Janssen Biotech, INC. | $814.18 | 2019-2025 | Stelara, Simponi Aria, Simponi |
| Nestle Healthcare Nutrition INC. | $481.13 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $437.24 | 2019-2024 | Linzess |
| Ferring Pharmaceuticals INC. | $236.66 | 2019-2022 | |
| Romark Laboratories, Lc | $230.86 | 2019-2020 | |
| Intra-Sana Laboratories | $215.15 | 2022-2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Boston Scientific Corporation | $186.37 | 2019-2024 | Compliance Endokit |
| Phathom Pharmaceuticals, INC. | $147.52 | 2024-2025 | Voquezna |
| Allergan, INC. | $118.74 | 2019 | |
| Redhill Biopharma INC. | $86.23 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $80.31 | 2023-2024 | Dupixent |
| Evoke Pharma, INC. | $62.01 | 2023-2025 | Gimoti |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Braintree Laboratories, INC. | $61.78 | 2022-2024 | Suflave |
| Madrigal Pharmaceuticals | $60.85 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $57.39 | 2024-2025 | Omvoh |
| Daiichi Sankyo INC. | $56.91 | 2023-2024 | Injectafer |
| Ucb, INC. | $52.98 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.07 | 2023-2025 | Xifaxan |
| Celltrion USA INC. | $34.16 | 2024 | Zymfentra |
| Octapharma USA, INC. | $33.92 | 2024 | Balfaxar |
| Shire North American Group INC | $33.23 | 2019 | |
| Aimmune Therapeutics, INC. | $24.03 | 2024 | |
| Alfasigma USA, INC. | $21.96 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $20.46 | 2023 | Zilretta, Iovera, Exparel |
| Medtronic, INC. | $20.29 | 2021 | |
| Genzyme Corporation | $20.16 | 2024 | |
| Covidien LP | $17.37 | 2020 | |
| Concordia Pharmaceuticals INC. | $14.12 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harold Silver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.